Introduction: Polio virus was found in London sewers; abortion bans in many states in the United States will take effect; Harvard University has developed a universal cancer vaccine, which may be able to treat a variety of cancers... Bioexploration will follow you to "medicine" news , explore the value of biotechnology!
01 Polio virus found in London sewers
On June 23, the British Health and Safety Authority and the World Health Organization both issued relevant statements that "polio (polio) virus was found in London wastewater." Sequencing the virus detected in the stool revealed it to be "vaccine-derived poliovirus (VDPV2)" and it is now thought the virus may have spread among people in close contact with each other. The virus has only been detected in wastewater, and no one has been found to have symptoms of polio. British public health officials are stepping up surveillance and are calling on parents to vaccinate their children with the polio vaccine on time.
02 Multi-state abortion bans in the United States will take effect
On June 24, The U.S. Supreme Court overturned the 1973 "Roe v. Wade" ruling, abolished the right to abortion stipulated in the Constitution, and left the legality of abortion to the states. , according to relevant reports, 13 states have begun to implement abortion bans based on "trigger laws." Lauren Frazier, a spokesperson for Planned Parenthood of Southeast Atlanta, said young women are worried their options for pregnancy are diminishing after the Supreme Court struck down constitutional protections for abortion. As a result, many people called the association to ask how many birth control pills they could stockpile. In addition, inquiries about emergency contraception , vasectomy and fallopian tube ligation are also increasing. For this reason, many mothers are actively stocking up on contraceptive pills for their children, but the surge in demand has prompted some retailers in the United States to restrict the purchase of over-the-counter emergency contraceptive pills.
03 Nature: Harvard University has developed a universal
cancer vaccine , which may be able to treat a variety of cancers
Recently, researchers from Harvard University published an article titled "A vaccine targeting resistant tumors by dual T cell plus NK" on Nature cell attack" research. In this study, the research team developed a new universal cancer vaccine that helps the patient's immune system eliminate the tumor defense system to destroy the cancer. It can induce different T cells and natural killer cells . Collaborative attack, thereby exerting more effective and broader immune function. Researchers say this universal vaccine may be useful in treating many types of cancer.
04 The entry quarantine time is shortened to "7+3"
html On June 28, The Joint Prevention and Control Mechanism of the State Council issued the "Novel Coronavirus Pneumonia Prevention and Control Plan (Ninth Edition)". Compared with the past, the ninth version of the prevention and control plan optimizes and adjusts the isolation management period and method of risk personnel. The isolation and control time for close contacts and immigrants has been adjusted from "14 days of centralized isolation medical observation + 7 days of home health monitoring" to "7 days of centralized isolation medical observation + 3 days of home health monitoring", and the close control measures for close contacts have been adjusted from "7 days of centralized isolation medical observation + 7 days of home health monitoring" "Centralized isolation and medical observation for 7 days" was adjusted to "home isolation for 7 days".05 FDA approves CD19's CAR-T cell therapy
for the precise treatment of large B-cell lymphoma
Recently, Bristol-Myers Squibb announced that the U.S. FDA has approved CD19's CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) for the treatment of large B-cell lymphoma. Large B-cell lymphoma in adults, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma. Breyanzi is a CD-19-directed chimeric antigen receptor T-cell therapy administered as a defined combination designed to reduce dosing variability of the CD8 and CD4 components. Breyanzi features a 4-1BB costimulatory domain that enhances T cell expansion and persistence.
finishing | Muzijiu
typesetting | Muzijiu
End
